Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. Recently, a randomized study of Pomalidomide and dexamethasone conducted in

bilateral oophorectomy
lenalidomide
induction therapy
cyclophosphamide
cancer
  • 33 views
  • 21 Jan, 2021
  • 3 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 29 Apr, 2021
  • 37 locations
Pomalidomide for the Treatment of Bleeding in HHT

This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who require parenteral

pomalyst
iron
parenteral infusion
epistaxis
platelet count
  • 0 views
  • 11 Mar, 2021
  • 10 locations
Pomalidomide Ixazomib and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in the study. After the first 6 patients will have finished the first …

lenalidomide
ixazomib
platelet count
cyclophosphamide
cell transplantation
  • 2 views
  • 25 Jan, 2021
  • 18 locations
Elotuzumab Pomalidomide & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal

stem cell transplantation
lenalidomide
pomalyst
bortezomib
corticosteroids
  • 4 views
  • 31 Jan, 2021
  • 5 locations
Daratumumab Pomalidomide and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab

proteasome inhibitor
lenalidomide
monoclonal antibodies
measurable disease
immunomodulatory imide drug
  • 0 views
  • 16 Apr, 2021
  • 10 locations
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib

bortezomib
dexamethasone
refractory multiple myeloma
lenalidomide
pomalidomide
  • 0 views
  • 26 Apr, 2021
  • 37 locations
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA

refractory multiple myeloma
lenalidomide
daratumumab
measurable disease
vasectomy
  • 79 views
  • 24 Jan, 2021
  • 48 locations
A Study Comparing JNJ-68284528 a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA) Versus Pomalidomide Bortezomib and Dexamethasone (PVd) or Daratumumab Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

The purpose of this study is to compare the efficacy of JNJ-68284528 with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone

proteasome inhibitor
lenalidomide
measurable disease
immunomodulatory imide drug
bcma
  • 161 views
  • 07 May, 2021
  • 104 locations
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive

proteasome inhibitor
dexamethasone
refractory multiple myeloma
lenalidomide
pomalidomide
  • 91 views
  • 14 May, 2021
  • 240 locations